Abstract
The aim of the present study is to develop and formulate a nanoparticulate carrier for sustained and ocular delivery of Fluconazole and to study its in-vitro release characters. Chitosan nanoparticles of Fluconazole were formulated by spontaneous emulsification and cross-linking method. The mean particle size, drug loading capacity, invitro release profile and release kinetics were studied. The antifungal efficacies of nanospheres were compared with conventional eye drops by cup-plate method. The average particle size was found to be 152.85±13.7nm. The drug loading capacity of all drug loaded nanoparticles was found to be optimum (≤50%). The in-vitro release study revealed the zero order kinetics and Higuchi’s diffusion mechanism. The drug bound nanoparticles exhibited good in-vitro antifungal effect in comparison with conventional eye drops. The formulated nanoparticles were found to be a suitable carrier for sustained ocular delivery of Fluconazole in terms of optimum drug loading, sustained release characters and antifungal activity.
Keywords: Chitosan, fluconazole, nanoparticles, ocular, sustained release.
Nanoscience & Nanotechnology-Asia
Title:In-vitro Characterization of Chitosan Nanoparticles of Fluconazole as a Carrier for Sustained Ocular Delivery
Volume: 7 Issue: 1
Author(s): Kumaraswamy Santhi, Selvadurai Muralidharan, Young H. Yee, Fong Y. Min, Chong Z. Ting and Durga Devi
Affiliation:
Keywords: Chitosan, fluconazole, nanoparticles, ocular, sustained release.
Abstract: The aim of the present study is to develop and formulate a nanoparticulate carrier for sustained and ocular delivery of Fluconazole and to study its in-vitro release characters. Chitosan nanoparticles of Fluconazole were formulated by spontaneous emulsification and cross-linking method. The mean particle size, drug loading capacity, invitro release profile and release kinetics were studied. The antifungal efficacies of nanospheres were compared with conventional eye drops by cup-plate method. The average particle size was found to be 152.85±13.7nm. The drug loading capacity of all drug loaded nanoparticles was found to be optimum (≤50%). The in-vitro release study revealed the zero order kinetics and Higuchi’s diffusion mechanism. The drug bound nanoparticles exhibited good in-vitro antifungal effect in comparison with conventional eye drops. The formulated nanoparticles were found to be a suitable carrier for sustained ocular delivery of Fluconazole in terms of optimum drug loading, sustained release characters and antifungal activity.
Export Options
About this article
Cite this article as:
Santhi Kumaraswamy, Muralidharan Selvadurai, Yee H. Young, Min Y. Fong, Ting Z. Chong and Devi Durga, In-vitro Characterization of Chitosan Nanoparticles of Fluconazole as a Carrier for Sustained Ocular Delivery, Nanoscience & Nanotechnology-Asia 2017; 7 (1) . https://dx.doi.org/10.2174/2210681206666160402003316
DOI https://dx.doi.org/10.2174/2210681206666160402003316 |
Print ISSN 2210-6812 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6820 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Apoptosis-Induction is A Novel Therapeutic Strategy for Gastrointestinal and Liver Cancers
Current Gene Therapy Flavonoids as Anticancer Agents: Structure-Activity Relationship Study
Current Medicinal Chemistry - Anti-Cancer Agents An Update on JAK Inhibitors
Current Medicinal Chemistry A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists
Current Medicinal Chemistry Every Cloud Has a Silver Lining: Proneurogenic Effects of Aβ Oligomers and HMGB-1 via Activation of the RAGE-NF-κB Axis
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Adrenergic Receptors as Targets for Cancer Treatment - A Perspective for Future Studies
Current Cancer Therapy Reviews Targets to Tackle – The Pathophysiology of the Disease
Current Drug Targets Current Status of Clinical Trials for Glioblastoma
Reviews on Recent Clinical Trials Small Artery Remodeling in Obesity and Insulin Resistance
Current Vascular Pharmacology NKT Cell-Stimulating Synthetic Glycolipids as Potential Therapeutics for Autoimmune Disease
Current Topics in Medicinal Chemistry Triamcinolone Acetonide Inhibits p38MAPK Activation and Neuronal Apoptosis in Early Diabetic Retinopathy
Current Molecular Medicine Anti-inflammatory Property of AMP-activated Protein Kinase
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pharmacological Targeting of the Epidermal Barrier
Current Pharmaceutical Design Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Prion Disease: Chemotherapeutic Strategies
Infectious Disorders - Drug Targets Effectors of Fatty Acid Oxidation Reduction: Promising New Anti-Ischaemic Agents
Current Pharmaceutical Design Demographic, Clinical, and Investigational Characteristics of COVID-19- related Guillain-Barré Syndrome with Differences from Typical and Another Virus-related Guillain-Barré Syndrome
Infectious Disorders - Drug Targets Design, Synthesis and Pharmacological Evaluation of Some Novel Tetrahydrocarbazoles as Potential COX-2 Inhibitors
Letters in Drug Design & Discovery Application of Carbon Monoxide for Transplantation
Current Pharmaceutical Biotechnology